Eltacin

Pharmacotherapeutic group: Antioxidant drug

ATC code: C01EX

Pharmacological properties:

Eltacin^® contains the mix of nonessential amino acids: Glycine, L-glutamic acid and L-cystine, which are act as a metabolic regulator: increase the intracellular level of glutathione and activity of glutathione-dependent enzymes, normalize oxidation-reduction processes and oxygen utilization in tissues; as a result, the drug is able to:

have an antioxidant (decreasing level of free radicals, peroxide compounds and malondialdehyde) and anti-hypoxic (increasing organism resistance to hypoxia, intensifying the ATP synthesis) effect;
enhance the myocardial contractility;
enhance physical tolerance;
enhance life quality of patients with heart failure (increasing the social integration, improving psycho-emotional state);
speed up recovery of working efficiency after strenuous exercise in children.

Indications

Chronic heart failure (I-III NYHA functional classes, on background of basic therapy) in adults;
chronic heart failure (I-II NYHA functional classes, on background of basic therapy) in children of 12-18 years;
vegetative dysfunction syndrome in children of 12-18 years;
prevention of chronic overexertion and recovery after strenuous exercise whilst sports activities in children of 11-15 years.

Contraindications

Individual hypersensitivity to the drug, age under 11 (efficiency and safety are not determined).

Pregnancyandlactation.

Clinical trials of Eltacin^® during pregnancy and lactation were not conducted. Not recommended to use during pregnancy and lactation.

Dosageandadministration:

Sublingually. It also possible to chew the tablet and place it under the tongue till it completely dissolve.

Chronic heart failure (I-III NYHA functional classes) in adults: 1 tablet 3 times a day sublingually; duration of the course is from 1 to 3 months (depends on severity of the disease); retreatment may be prescribed by a doctor.

Chronic heart failure (I-II NYHA functional classes) in children of 12-18 years: 1 tablet 3 times a day sublingually; duration of the course is from 1 to 3 months (depends on severity of the disease); retreatment may be prescribed by a doctor.

Vegetative dysfunction syndrome in children of 12-18 years: 1 tablet 3 times a day sublingually; duration of the course is from 1 to 3 months (depends on severity of the disease); retreatment may be prescribed by a doctor.

Prevention of chronic overexertion in children of 11-15 years: 1 tablet 2 times a day for 2-3 weeks.

Recovery after strenuous exercise whilst sports activities in children of 11-15 years: 1 tablet 3 times a day for 2 weeks.

Adverse reactions

Allergic reactions are possible.

Overdosage

No cases of overdose occured.

Drug interactions

There is no information about drug interactions.

Precautions

It is possible to take Eltacin^® together with angiotensin-converting enzyme inhibitors, beta-blockers, diuretics, aldosterone antagonists, organic nitrates, and calcium channel-blocking agents.

Dosage form

70 mg + 70 mg + 70 mg sublingual tablets.

Blister with 30 tablets in cardboard pack together with the patient information leaflet.

Storage conditions

Store in a dry place at a temperature under 25 °C, protect from light.

Keep out of the reach of children.

Shelf life

3 years. Do not use after labeled expiration date.

Prescription status

No prescription required.

Manufacturer / For reclamations:

Ltd. “Medical Research and Production Complex “BIOTIKI”